Öz
Giriş
Glekaprevir/pibrentasvir (G/P), kronik hepatit C virüsü (HCV) enfeksiyonu olan yetişkinlerin tedavisi için onaylanmış, pan-genotipik, doğrudan etkili bir antiviral rejimdir. Bu çalışmanın amacı, kronik HCV hastalarında G/P’in gerçek yaşam etkinliğini ve güvenliğini araştırmaktır.
Gereç ve Yöntem
1 Ocak 2021 ile 1 Mart 2024 tarihleri arasında, kronik HCV enfeksiyonu için G/P tedavisi başlanan, tespit edilebilir HCV-RNA’sı olan, 18 yaş üstü hastalar analiz edildi. Birincil sonlanım noktası olan sürekli virolojik yanıt (SVR), tedavinin tamamlanmasından 12 hafta sonra tespit edilemeyen HCV-RNA olarak tanımlandı. Ayrıca G/P’nin güvenliği ve tolere edilebilirliği de değerlendirildi.
Bulgular
Toplam 191 hasta (%85,5 erkek) G/P ile tedavi edildi. Bunlardan 124’ü (%64,9) intravenöz uyuşturucu kullanıcısıydı. En yaygın genotip (GT) GT 3’tü (%57,1). Tedavinin tamamlanmasından on iki hafta sonra, 105 hasta takibe katıldı ve hepsi SVR12’ye ulaştı. Yan etki 12 hastada (%6,3) gözlendi. Bir hastada tedavi, 4. Haftada, kaşıntı ve döküntü nedeniyle kesildi.
Sonuç
G/P, kronik HCV enfeksiyonu olan hastalar için oldukça etkili, iyi tolere edilen ve güvenli bir pan-genotipik tedavi seçeneğidir.
Anahtar Kelimeler: Hepatit C virüsü, tedavi, glecaprevir, pibrentasvir
Kaynakça
Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol. 2013;10:553-62.
Global hepatitis report 2024: action for access in low- and middle-income countries. Geneva: World Health Organization; 2024.
Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect. 2015;21:1020-6.
Gürbüz Y, Tülek NE, Tütüncü EE, Koruk ST, Aygen B, Demirtürk N, Kınıklı S, Kaya A, Yıldırmak T, Süer K, Korkmaz F, Ural O, Akhan S, Günal Ö, Tuna N, Köse Ş, Gönen İ, Örmen B, Türker N, Saltoğlu N, Batırel A, Tuncer G, Bulut C, Sırmatel F, Ulçay A, Karagöz E, Tosun D, Şener A, Aynıoğlu A, Altunok ES. Evaluation of dual therapy in real life setting in treatment-naïve Turkish patients with HCV infection: a multicenter, retrospective study. Balkan Med J. 2016;33:18-26.
Gürbüz Y, Kocagül-Çelikbaş A, Öztoprak N, Aygen B, Batırel A, Habiloğlu AD, Aktuğ-Demir N, Çeken S, Demirtürk N, Ceylan MR, Üçer Ş, Karakeçili F, Alkan S, İnce N, Akça A, Günay V, Mustanoğlu-Özatağ D, Çınar G, Kınıklı S, Yıldız O, Şarlak-Konya P, Sümer Ş, Yekenkurul D, Çelik M, Binay UD, Aşık-Otman Z. The efficacy of glecaprevir/pibrentasvir in chronic hepatitis C patients and the impact of the COVID-19 pandemic: multicenter real-life data. Infect Dis Clin Microbiol. 2024;6:216-24.
Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL, Hassanein T, Felizarta F, Sulkowski MS, Gane E, Maliakkal B, Overcash JS, Gordon SC, Muir AJ, Aguilar H, Agarwal K, Dore GJ, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol. 2017;67:263-71.
Yamana Y, Kanda T, Matsumoto N, Honda M, Kumagawa M, Sasaki R, Kanezawa S, Mizutani T, Yamagami H, Masuzaki R, Ishii T, Nirei K, Moriyama M. Efficacy of glecaprevir/pibrentasvir for real-world HCV infected patients in the northern part of Tokyo, Japan. J Clin Med. 2021;10:5529.
D’Ambrosio R, Pasulo L, Puoti M, Vinci M, Schiavini M, Lazzaroni S, Soria A, Gatti F, Menzaghi B, Aghemo A, Capelli F, Rumi MG, Morini L, Giorgini A, Pigozzi MG, Rossini A, Maggiolo F, Pan A, Memoli M, Spinelli O, Del Poggio P, Saladino V, Spinetti A, De Bona A, Capretti A, Uberti-Foppa C, Bonfanti P, Terreni N, Menozzi F, Colombo AE, Giglio O, Centenaro R, Borghi M, Baiguera C, Picciotto V, Landonio S, Gori A, Magnani C, Noventa F, Paolucci S, Lampertico P, Fagiuoli S; NAVIGATORE-Lombardia Study Group. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol. 2019;70:379-87.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, S Sulkowski M, Torriani FJ, Dieterich DT, Thomas DL, Messinger D, Nelson M; APRICOT Clinical Investigators. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;43:1317-25.
Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-26.
Müllhaupt B, Semela D, Ruckstuhl L, Magenta L, Clerc O, Torgler R, Negro F, Semmo N. Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Med Wkly. 2021;151:w20399.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2020. J Hepatol 2020 in press.
Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med. 2018;378:354-69.
Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, Beyer J, Dekhtyar T, Irvin M, Xie W, Larsen L, Mensa FJ, Collins C. Pooled resistance analysis in patients with hepatitis C virus genotype 1 to 6 infection treated with glecaprevir-pibrentasvir in phase 2 and 3 clinical trials. Antimicrob Agents Chemother. 2018;62:e01249-18.
Martinello M, Bhagani S, Shaw D, Orkin C, Cooke G, Gane E, Iser D, Ustianowski A, Kulasegaram R, Stedman C, Tu E, Grebely J, Dore GJ, Nelson M, Matthews GV. Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study. JHEP Rep. 2023;5:100867.
Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, Şeydaoğlu G, Özkarataş E, Abacıoğlu H. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol. 2020;31:128-35.
Wei L, Wang G, Alami NN, Xie W, Heo J, Xie Q, Zhang M, Kim YJ, Lim SG, Fredrick LM, Lu W, Liu W, Kalluri HV, Krishnan P, Tripathi R, Mobashery N, Burroughs M, Asatryan A, Jia J, Hou J. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol. 2020;5:839-9.
Alswat K, Al-Sohaibani F, Khathlan A, Bashmail A, Alanazi M, Kurdi A, Almakadma AH, Al-Hamoudi W. Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals. Ann Saudi Med. 2022;42:89-95.
Bachofner JA, Valli PV, Kröger A, Bergamin I, Künzler P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terziroli Beretta-Piccoli B, Mertens JC. Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int. 2017;37:369-76.
Tufan AG, Hakim GD, Akar H, Akarsu M. Evaluation of fibrosis in chronic hepatitis C patients treated with direct-acting antivirals. Hepatol Forum. 2020;1:53-8.
Puoti M, Foster GR, Wang S, Mutimer D, Gane E, Moreno C, Chang TT, Lee SS, Marinho R, Dufour JF, Pol S, Hezode C, Gordon SC, Strasser SI, Thuluvath PJ, Zhang Z, Lovell S, Pilot-Matias T, Mensa FJ. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol. 2018;69:293-300.
